Chemical compounds
The invention is directed to certain novel compounds. Specifically, the invention is directed to compounds of formula (I): and salts thereof. The compounds of the invention are inhibitors of kinase activity, in particular PI3-kinase activity.
1. A method of treating a disorder mediated by inappropriate PI3-kinase activity comprising administering an amount of a compound of formula (I):
wherein
R 1 is C 1-6 alkoxy or —N(C 1-6 alkyl) 2 ,
R 2 is hydrogen or C 1-6 alkyl optionally substituted by —C(O)OC 1-6 alkyl or —OC(O)C 1-6 alkyl,
R 3 , R 4 , R 5 and R 6 are each independently selected from hydrogen and halogen;
R 7 and R 8 are each independently C 1-6 alkyl, or
R 7 and R 8 , together with the nitrogen atom to which they are attached, are linked to form a 5- or 6-membered heterocyclyl wherein the 5- or 6-membered heterocyclyl optionally contains a further nitrogen atom and is optionally substituted by C 3-6 cycloalkyl, 4- to 6-membered heterocyclyl containing one or two heteroatoms independently selected from oxygen and nitrogen, or C 1-6 alkyl wherein the C 1-6 alkyl is optionally substituted by hydroxy or C 1-6 alkoxy, or
R 7 and R 8 , together with the nitrogen atom to which they are attached, are linked to form a 5- or 6-membered heterocyclyl wherein the 5- or 6-membered heterocyclyl contains an oxygen atom and is optionally substituted by one or two substituents independently selected from C 1-6 alkyl;
or a pharmaceutically acceptable salt thereof, to a patient in need thereof, by inhibiting PI3-kinase activity and wherein said disorder mediated by inappropriate PI3-kinase activity is selected from the group consisting of asthma and COPD.
2. A method according to claim 1 wherein the disorder mediated by inappropriate PI3-kinase activity is asthma.
3. A method according to claim 1 wherein the disorder mediated by inappropriate PI3-kinase activity is COPD.